EyePoint Q3 2026 net loss widens 60% to $95.6 million

By Public Technologies
  • EyePoint’s third-quarter 2026 net loss widened 60% to $95.6 million, while total net revenue fell 20% to $800,000.
  • Operating expenses jumped 55% to $97.6 million, primarily due to ongoing DURAVYU Phase 3 trials for wet AMD and DME.
  • A planned 53% workforce reduction and operational adjustments are expected to generate approximately $30 million in annualized savings.
  • Resources will prioritize DURAVYU’s fully enrolled Phase 3 DME trials, with topline data expected early in the fourth quarter of 2027.
  • Cash, cash equivalents and marketable securities totaled $118 million at September 30, 2026; projected funding extends into late third-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456889), on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.